Nabriva Therapeutics, which is developing a novel antibiotic for bacterial pneumonia, announced terms for its IPO on Tuesday.
The Vienna, Austria-based company plans to raise $96 million by offering 6.0 million ADSs at a price range of $15 to $17. At the midpoint of the proposed range, Nabriva Therapeutics would command a fully diluted market value of $280 million.
Novartis (NYSE: NVS) is listed as a top shareholder.
Nabriva Therapeutics, which was founded in 2005, plans to list on the Nasdaq under the symbol NBRV. Leerink Partners and RBC Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of September 14, 2015.
